Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001708599-25-000053
Filing Date
2025-05-08
Accepted
2025-05-08 16:10:21
Documents
74
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ser-20250331.htm   iXBRL 10-Q 800912
2 EX-31.1 ser-20250331xexx311.htm EX-31.1 9462
3 EX-31.2 ser-20250331xexx312.htm EX-31.2 9566
4 EX-32 ser-20250331xexx32.htm EX-32 4933
  Complete submission text file 0001708599-25-000053.txt   5607454

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250331.xsd EX-101.SCH 45462
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ser-20250331_cal.xml EX-101.CAL 64030
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ser-20250331_def.xml EX-101.DEF 193057
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250331_lab.xml EX-101.LAB 572971
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250331_pre.xml EX-101.PRE 399176
77 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250331_htm.xml XML 664170
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38519 | Film No.: 25926147
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)